ArticleChemistry & biodiversity2026
Antifungal Activity and Possible Mechanism of Action of the Zn (II) Complex With a Schiff Base Against Fluconazole-Resistant Strains of Candida spp. and Cryptococcus neoformans.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to investigate the antifungal activity of the vanillin-derived Schiff base complexed with zinc (II) (SBZ) against fluconazole-resistant strains of Candida spp. and Cryptococcus neoformans. The broth microdilution assay was performed to determine the minimum inhibitory concentration (MIC). The checkerboard assay was used to evaluate the type of pharmacological interaction of the combination of SBZ with azoles. Flow cytometry and alkaline comet assays were performed to investigate the possible action mechanism of SBZ against Candida albicans and Cryptococcus neoformans. The MIC values of SBZ for Candida spp. ranged from 24 to 74.7 µg/mL and for C. neoformans from 32 to 53.3 µg/mL. The combination of SBZ with both fluconazole and itraconazole resulted in additive and indifferent interactions, respectively. The mechanism of action appears to involve mitochondrial depolarization, increased oxidative stress, and DNA damage, leading to apoptosis. Thus, the SBZ complex shows promising in vitro antifungal activity, and its combination with azoles may contribute to optimizing the efficacy of these drugs, justifying future in vivo investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.